Sotio
SOTIO Biotech is a clinical-stage biopharmaceutical company owned by PPF Group, developing targeted immuno-oncology therapies — IL-15 superagonists, antibody-drug conjugates, and CAR-T cell therapies — for patients with solid tumors including sarcoma and gastrointestinal cancers.
- Company typePrivate
- Founded2013
- HeadquartersPrague, Czechia
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Sotio does
SOTIO Biotech a.s. is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Prague, Czech Republic, wholly owned by PPF Group. The company develops targeted immuno-oncology therapies for solid tumors, organized across three principal technology platforms: IL-15 superagonist immunocytokines (nanrilkefusp alfa, SOT201), antibody-drug conjugates built on four licensed chemistries (SOT102, SOT106, SOT109, SOT113, SOT114), and enhanced CAR-T cell therapy (BOXR1030). Earlier-stage DCVAC dendritic cell vaccines for prostate, ovarian, and lung cancer complete the portfolio. SOTIO operates as the integration layer for multiple in-licensed platform technologies, applying its pipeline strategy of matching proprietary antibodies to the optimal ADC conjugation chemistry per target.
SOTIO has no commercialized products and generates no product revenue. Its business model is R&D-driven: advance candidates through Phase 1/2 trials (VICTORIA-01, CLAUDIO-01, AURELIO-04/05, DUET-01) toward potential regulatory approval and eventual commercialization through standard pharmaceutical distribution channels. Funding flows from parent PPF Group, demonstrated by a €280 million round in December 2021, supplemented by non-dilutive milestone potential from technology partners. Capital allocation reflects heavy investment in clinical development, scientific publications, and conference engagement rather than traditional sales or marketing infrastructure. The company employs between 251 and 500 staff across offices in Prague, Boston (US regional office), Basel, and Amsterdam.
The company's go-to-market approach is enterprise-focused, engaging directly with regulatory bodies (FDA, EMA), clinical trial sites, healthcare institutions, and biopharma partners. Strategic alliances include MSD supplying KEYTRUDA for the AURELIO-04 Phase 2 combination trial, LigaChem Biosciences, Synaffix B.V. (a Lonza company), NBE-Therapeutics, and Biocytogen. Distribution post-approval is expected through hospital pharmacies, specialty pharmacies, and direct physician prescribing. SOTIO's customer base in the near term is clinical trial patients with advanced solid tumors; the addressable population spans sarcoma, osteosarcoma, colorectal, gastric, pancreatic, esophageal, lung, ovarian, and prostate cancers.
Sotio firmographics
Firmographics- Name
- Sotio
- Legal name
- SOTIO Biotech a.s.
- Website
- https://sotio.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- SOTIO Biotech is a clinical-stage biopharmaceutical company owned by PPF Group, developing targeted immuno-oncology therapies — IL-15 superagonists, antibody-drug conjugates, and CAR-T cell therapies — for patients with solid tumors including sarcoma and gastrointestinal cancers.
- Ownership category
- akta.pro rank
Sotio industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where Sotio is headquartered
LocationHeadquarters
- HQ city
- Prague
- HQ country
- Czechia
- HQ region
- Europe
Offices4 records
Markets served
Sotio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Revenue: SOTIO is a clinical-stage biopharmaceutical company with no commercialized products currently generating revenue. The company is focused on advancing its pipeline of targeted cancer therapies through clinical development toward regulatory approval and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Sotio product offering
Product offeringCore offering
SOTIO Biotech is a clinical-stage biopharmaceutical company developing a pipeline of targeted cancer immunotherapies for the treatment of solid tumors. Its offerings center on four proprietary technology platforms: IL-15 Superagonist immunocytokines (nanrilkefusp alfa, SOT201), Antibody-Drug Conjugates (SOT102, SOT106, SOT109, SOT113, SOT114), BOXR CAR-T cell therapies (BOXR1030), and dendritic cell-based vaccines (DCVAC). The products are investigational and not yet commercially available, with future distribution planned through hospital pharmacies, specialty pharmacies, and physician prescribing upon regulatory approval.
Product overview
SOTIO Biotech is a clinical-stage biopharmaceutical company owned by PPF Group, developing targeted cancer therapies with first-in-class and best-in-class potential. The company's robust pipeline includes both internally developed and in-licensed candidates organized across multiple technology platforms: IL-15 Superagonist immunotherapies (nanrilkefusp alfa and SOT201 immunocytokine), Antibody-Drug Conjugates (SOT102, SOT106, SOT109, SOT113, SOT114), BOXR CAR-T cell therapies (BOXR1030), and dendritic cell-based vaccines (DCVAC product line). SOTIO has established multiple strategic partnerships for ADC technology including platforms from NBE-Therapeutics, LigaChem Biosciences (ConjuAll™), Synaffix (GlycoConnect®, HydraSpace®), and Biocytogen (RenLite®).
Differentiator
Problem solved
Functional benefit
Brands
- SOTIO Biotech Pipeline: Company's portfolio of immuno-oncology assets including IL-15 superagonists and antibody-drug conjugates
Products and services
- Nanrilkefusp alfa (formerly SOT101) A subcutaneously-administered IL-15 superagonist fused to the sushi+ domain of the IL-15 receptor α, designed to selectively bind cytotoxic T and NK cells while avoiding other cell types associated with adverse events, for the treatment of advanced solid tumors including in the AURELIO-04/05 Phase 2 trial.
- SOT201 An immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody to directly target T cells, enabling spatial colocalization of IL-15 superagonist with anti-PD-1 checkpoint inhibitor for enhanced synergistic effects. One of the first IL-15/PD-1 targeting immunocytokines, currently in VICTORIA-01 Phase 1 clinical trial.
- SOT102 A CLDN18.2-targeting antibody-drug conjugate (ADC) in Phase 1/2 development for the treatment of gastric, pancreatic, and other cancers with limited targeted treatment options, evaluated in the CLAUDIO-01 study.
- SOT106 An ADC targeting leucine-rich repeat containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and tumor associated stroma, based on LigaChem Biosciences' ConjuAll™ ADC platform technology. Currently in advanced preclinical development with focus on soft tissue sarcoma and osteosarcoma; FDA Orphan Drug Designation granted in June 2026.
- SOT109 An ADC candidate targeting cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers and abundantly expressed in other GI cancers including gastric, pancreatic, and esophageal cancers. Utilizes the Synaffix GlycoConnect-HydraSpace conjugation platform with exatecan payload.
- SOT113 and SOT114 Next-generation bispecific ADCs against undisclosed targets in preclinical development for the treatment of solid tumors, leveraging Biocytogen's RenLite bispecific antibody platform.
- BOXR1030 A metabolically enhanced CAR T-cell therapy with an innovative chimeric PGC-1α transgene to boost CAR T cell efficacy in patients with solid tumors, currently in the DUET-01 Phase 1/2 first-in-human study.
- DCVAC product line (DCVAC/PCa, DCVAC/OvCa, DCVAC/LuCa) Dendritic cell-based active cellular immunotherapy products including DCVAC/PCa for prostate cancer, DCVAC/OvCa for ovarian cancer, and DCVAC/LuCa for lung cancer.
Quantifiable outcome
- SOT106 demonstrated strong anti-tumor activity in preclinical studies in both soft tissue and osteosarcoma models with favorable tolerability
- +2 more outcomes
Companies that use Sotio
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Sotio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Sotio partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- MSD (Merck & Co., Inc.)flagshipMSD is supplying KEYTRUDA (pembrolizumab) for SOTIO's AURELIO-04 Phase 2 clinical trial combining SOT101 (nanrilkefusp alfa) with anti-PD-1 therapy in patients with advanced solid tumors. Clinical trial conducted in Europe and US.
- BiocytogencoreResearch collaboration and exclusive option and license agreement granting SOTIO option to license multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite and RenMab platforms to develop ADCs targeting solid tumors. Biocytogen eligible for upfront and potential milestone payments up to $325.5 million.
- Synaffix B.V. (Lonza company)coreLicense and option agreement enabling SOTIO to combine its proprietary antibodies with Synaffix's GlycoConnect, HydraSpace, and potent linker-payload platforms to develop up to three novel ADCs. Synaffix eligible to receive upfront and potential milestone payments up to $740 million plus single-digit royalties on net sales.
- NBE-TherapeuticscoreSOTIO is developing two ADCs in partnership with NBE-Therapeutics based on NBE's proprietary site-specific SMAC conjugation platform. These ADCs utilize anthracycline toxin PNU that leads to immunogenic cell death and elicits long-lasting anti-tumor immune response.
- LigaChem Biosciences (LegoChem)coreMulti-target exclusive collaboration and license agreement granting SOTIO rights to deploy LigaChem's ConjuAll ADC conjugation technology for up to five therapeutic programs. SOTIO exercised first option for SOT106 targeting LRRC15. SOTIO responsible for research, development, manufacturing and worldwide commercialization.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Sotio competitors and assessment
Company assessmentBroad incumbents
- ImmunoGen (AbbVie): Pioneer of ADC technology (Elahere approved for ovarian cancer), now owned by AbbVie — broader, established ADC player with commercial infrastructure serving similar oncology indications.
Direct peers
- Bolt Biotherapeutics: Clinical-stage developer of ISAC (Immune-Stimulating Antibody Conjugate) platform combining ADC payloads with immune activation — comparable targeted immuno-oncology approach.
- ADC Therapeutics: Commercial-stage ADC developer (Zynlonta approved) with pipeline targeting solid and hematologic tumors — closely comparable platform technology and clinical-stage development model.
- MacroGenics: Clinical-stage developer of bispecific antibodies, ADCs (vobramitamab duocarmazine), and immuno-oncology agents — directly comparable multi-platform antibody-based oncology approach.
- Innate Pharma: Clinical-stage immuno-oncology company developing NK cell engagers and antibodies — directly comparable immunology-focused oncology pipeline targeting similar mechanisms.
- Mersana Therapeutics: Clinical-stage biotech developing ADCs using proprietary Dolaflexin and Dolasynthen platforms targeting solid tumors — directly comparable to SOTIO's ADC strategy and pipeline stage.
- Pyxis Oncology: Clinical-stage ADC and immuno-oncology developer with multiple ADC programs targeting solid tumors — closely matches SOTIO's platform combination approach.
- CytomX Therapeutics: Clinical-stage biotech developing masked Probody ADCs and immune activators for oncology — directly comparable ADC-focused platform and clinical-stage pipeline.
Emerging players
- Werewolf Therapeutics: Clinical-stage biotech developing INDUKINE conditionally activated cytokines for solid tumors — comparable emerging cytokine-focused immuno-oncology approach with PREDATOR platform.
- Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for solid tumors (CTX-009, CTX-112) — comparable emerging-stage multi-platform immuno-oncology strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Sotio social profiles
Digital presenceSotio compliance and trust
Trust signalCompliance3 records
Sotio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sotio leadership team
Management profileNumber of profiles
Profiles6 records
Sotio subsidiaries and ownership
Company hierarchySubsidiaries3 records
Sotio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sotio M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sotio
What does Sotio do?
SOTIO Biotech is a clinical-stage biopharmaceutical company developing a pipeline of targeted cancer immunotherapies for the treatment of solid tumors. Its offerings center on four proprietary technology platforms: IL-15 Superagonist immunocytokines (nanrilkefusp alfa, SOT201), Antibody-Drug Conjugates (SOT102, SOT106, SOT109, SOT113, SOT114), BOXR CAR-T cell therapies (BOXR1030), and dendritic cell-based vaccines (DCVAC). The products are investigational and not yet commercially available, with future distribution planned through hospital pharmacies, specialty pharmacies, and physician prescribing upon regulatory approval.
Is Sotio a public or private company?
Sotio is a private company. It is classified as corporate owned and is currently operating.
When was Sotio founded?
Sotio was founded in 2013. It employs 251 to 500 people.
Where is Sotio based?
Sotio is headquartered in Prague, Czechia, in the Europe region.
How does Sotio make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Sotio's main competitors?
ImmunoGen (AbbVie) is listed as a broad incumbent. Direct peers are Bolt Biotherapeutics, ADC Therapeutics, MacroGenics, Innate Pharma, Mersana Therapeutics, Pyxis Oncology and CytomX Therapeutics. Emerging players are Werewolf Therapeutics and Compass Therapeutics.
Does Sotio have an API?
No public API is recorded for Sotio.
What industry is Sotio in?
Sotio's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2836.